Therapy Directory

Azacitidine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention. Browse Azacitidine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

132

Shown on this page

Current sort

Stored official records

Open in full search

Conditions: Acute Myeloid Leukemia, Haematological Malignancy, Higher-risk Myelodysplastic Syndrome, Multiple Myeloma, Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Interventions: Azacitidine, Bortezomib, CCS1477, Daratumumab, Dexamethasone, Elranatamab, Ixazomib, Lenalidomide, Pomalidomide, Teclistamab, Venetoclax; Drug
Lead sponsor: CellCentric Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax; Drug · Procedure
Lead sponsor: Alice Mims; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more

Conditions: Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions: Azacitidine; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndrome
Interventions: Azacitidine, SL-401, Venetoclax; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, NK Cells, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Placebo, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Interventions: Azacitidine, Cladribine, Cytarabine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Nivolumab, Oral Azacitidine; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cerebral Palsy
Interventions: 5-Azacitidine, Placebo, Smart Ankle-Foot Orthosis; Drug · Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 8 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cerebral Palsy
Interventions: 5-Azacitidine, Functional Activity Training, Mannitol, tSCS; Drug · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 4 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Q702, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

About this Azacitidine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Azacitidine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Azacitidine clinical trials

Filter and sort this therapy

Stored official records

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

About this Azacitidine clinical trials directory page